NextCure, Inc. (NXTC) - Q2 2025 10-Q Summary
Business Context and Reporting Period
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients. This report covers the quarterly period ended June 30, 2025. The company operates as a non-accelerated filer and smaller reporting company. All share and per-share data have been retrospectively adjusted to reflect a 1-for-12 reverse stock split effective July 14, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(26.8) million | $(15.4) million | $(37.8) million | $(32.5) million |
| Net Loss Per Share | $(11.29) | $(6.61) | $(16.05) | $(13.96) |
| Operating Expenses | $27.3 million | $16.5 million | $38.9 million | $34.8 million |
| Cash & Marketable Securities | $35.3 million (as of June 30, 2025) | |||
| Accumulated Deficit | $417.9 million (as of June 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | N/A | $(35.7) million | $(22.4) million |
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by $11.7 million in Q2 2025 compared to Q2 2024. This was primarily driven by a $17.0 million upfront payment for a new license agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming) for the ADC candidate SIM0505.
- Reduced G&A: General and administrative expenses decreased by $0.9 million in Q2 2025, largely due to lower personnel-related costs and reduced stock-based compensation.
- Cash Burn: Net cash used in operating activities for the six months ended June 30, 2025, was $35.7 million, an increase from $22.4 million in the prior year period, reflecting the higher R&D outlays.
- Equity Financing: The company raised $2.0 million in the quarter through a private placement of 338,636 shares to Simcere Zaiming, Inc., initially classified as mezzanine equity due to registration contingencies.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the report issuance. While cash reserves of $35.3 million are projected to fund operations into mid-2026, the company anticipates continued net losses and will require additional capital.
- Pipeline Progress:
- LNCB74: Phase 1 trial is ongoing; cohort 3 cleared in June 2025, currently in cohort 4. Proof of concept data expected in H1 2026.
- SIM0505: New license acquired in June 2025. First patient dosing anticipated in Q3 2025.
- Reverse Stock Split: A 1-for-12 reverse stock split was effectuated on July 14, 2025, to regain compliance with Nasdaq listing requirements. The company received confirmation of compliance on July 28, 2025.
- Risk Factors: Key risks include the inability to raise additional capital on acceptable terms, the uncertainty of clinical trial outcomes, and the potential need to delay or terminate development programs if funding is insufficient.
Investor Verification Checklist
- Verify the timeline and terms of the $17 million upfront payment to Zaiming and the remaining $5 million contingent payment due by December 31, 2025.
- Confirm the status of the mezzanine equity reclassification following the SEC registration of the Simcere Zaiming shares (completed July 29, 2025).
- Monitor cash burn rates against the mid-2026 liquidity runway projection.
- Review upcoming clinical milestones for LNCB74 (cohort 4 completion) and SIM0505 (first patient dosing) in Q3/Q4 2025.
- Assess the impact of the 1-for-12 reverse stock split on share liquidity and market price.